ArticleJournal of diabetes research2018

Treatment Discontinuation and Clinical Events in Type 2 Diabetes Patients Treated with Dipeptidyl Peptidase-4 Inhibitors or NPH Insulin as Third-Line Therapy.

Cristiano S Moura et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.